Cargando…

Response to Comment on: Gorboulev et al. Na(+)-d-glucose Cotransporter SGLT1 Is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion. Diabetes 2012;61:187–196

Detalles Bibliográficos
Autores principales:	Koepsell, Hermann, Gorboulev, Valentin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Online Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357261/ http://dx.doi.org/10.2337/db12-0061

Ejemplares similares

Comment on: Gorboulev et al. Na(+)-D-glucose Cotransporter SGLT1 Is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion. Diabetes 2012;61:187–196
por: Kellett, George L.
Publicado: (2012)

Na(+)-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
por: Gorboulev, Valentin, et al.
Publicado: (2012)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Conformational Dynamics of hSGLT1 during Na(+)/Glucose Cotransport
por: Loo, Donald D.F., et al.
Publicado: (2006)

Loss of Endometrial Sodium Glucose Cotransporter SGLT1 is Detrimental to Embryo Survival and Fetal Growth in Pregnancy
por: Salker, Madhuri S., et al.
Publicado: (2017)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Antidiabetic Effects of a Tripeptide That Decreases Abundance of Na(+)-d-glucose Cotransporter SGLT1 in the Brush-Border Membrane of the Small Intestine
por: Otto, Christoph, et al.
Publicado: (2020)

Active site voltage clamp fluorometry of the sodium glucose cotransporter hSGLT1
por: Gorraitz, Edurne, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing
por: Röder, Pia V., et al.
Publicado: (2014)

Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells
por: Wakisaka, Masanori, et al.
Publicado: (2016)

Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes
por: Ko, Hwa Yeon, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
por: Sano, Motoaki
Publicado: (2020)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
por: Nakano, Dan, et al.
Publicado: (2022)

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

Structure–Activity Relationship Study of Acyclic Terpenes in Blood Glucose Levels: Potential α-Glucosidase and Sodium Glucose Cotransporter (SGLT-1) Inhibitors
por: Valdes, Miguel, et al.
Publicado: (2019)

Comment on: Teeuwisse et al. Short-Term Caloric Restriction Normalizes Hypothalamic Neuronal Responsiveness to Glucose Ingestion in Patients With Type 2 Diabetes. Diabetes 2012;61:3255–3259
por: Heni, Martin, et al.
Publicado: (2013)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?
por: Ujjawal, Aditi, et al.
Publicado: (2022)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance
por: Yamane, Shunsuke, et al.
Publicado: (2011)

Response to Comment on: Teeuwisse et al. Short-Term Caloric Restriction Normalizes Hypothalamic Neuronal Responsiveness to Glucose Ingestion in Patients With Type 2 Diabetes. Diabetes 2012;61:3255–3259
por: Widya, Ralph L., et al.
Publicado: (2013)

Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
por: Salehi, Marzieh, et al.
Publicado: (2012)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Role of fasting duration and weekday in incretin and glucose regulation
por: Clemmensen, Kim K B, et al.
Publicado: (2020)

Role of fasting duration and weekday in incretin and glucose regulation
por: Clemmensen, Kim K B, et al.
Publicado: (2021)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018)

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rm04b7l1tno0t017svnae4lks7